Positive MIBG scanning at the time of relapse in neuroblastoma which was MIBG negative at diagnosis.
- 1 January 1997
- journal article
- case report
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 70 (829) , 90-92
- https://doi.org/10.1259/bjr.70.829.9059302
Abstract
Metaiodobenzylguanidine (MIBG) labelled with iodine-123 (123I) or 131I has become a well established tool with high sensitivity and specificity in the diagnosis and staging of neuroblastoma in children. However, some neuroblastomas do not take up MIBG at the time of diagnosis. The reasons for this are unclear but may be related to uptake mechanisms. Follow-up MIBG scans have not been reported in these patients. We present a case where an initial 123I-MIBG-scan was negative at diagnosis but became positive when the patient relapsed. This unusual occurrence may have implications for patients with a negative MIBG-scan at presentation. These patients should be re-evaluated by MIBG-scan at the time of relapse as a positive scan then offers the possibility of additional treatment with MIBG therapy.Keywords
This publication has 6 references indexed in Scilit:
- Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.Journal of Clinical Oncology, 1993
- Neuroblastoma: dose-related sensitivity of MIBG scanning in detection.Radiology, 1992
- I-131 MIBG imaging after bone marrow transplantation for neuroblastoma.Radiology, 1992
- Treatment of neuroblastoma with 131I‐MIBG: Dosimetric problems and perspectivesMedical and Pediatric Oncology, 1987
- Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow‐up treatment with a review of the diagnostic results of the international workshop of pediatric oncology held in Rome, september 1986Medical and Pediatric Oncology, 1987
- Summary of discussion, conclusions, and recommendations: MIBG symposiumMedical and Pediatric Oncology, 1987